Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
19 nov. 2024 01h00 HE
|
Biogen Inc.
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14 nov. 2024 16h30 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
14 nov. 2024 16h05 HE
|
Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
18 oct. 2024 10h56 HE
|
Spherix Global Insights
EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
11 oct. 2024 12h12 HE
|
Tevogen Bio Inc
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
10 oct. 2024 10h28 HE
|
Spherix Global Insights
EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.
03 oct. 2024 02h00 HE
|
Citryll
CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical...
US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights
02 oct. 2024 12h27 HE
|
Spherix Global Insights
EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. Common symptoms include...
Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights
25 sept. 2024 08h16 HE
|
Spherix Global Insights
EXTON, PA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial firms...
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
23 sept. 2024 10h18 HE
|
Spherix Global Insights
EXTON, PA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late...